Find Clinical Trial

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation


← Back
Study Phase

Phase 3

Therapeutic Area

Cancers

IndicationAcute Myeloid Leukemia
SponsorInstitut de Recherches Internationales Servier
Active substance/
Medical device

AG-120, Ivosidenib

Active Substance CodeAG-120
Protocol CodeAG120-C-009
EudraCT Code2016-004907-30
NCT CodeNCT03173248


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility